<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01861847</url>
  </required_header>
  <id_info>
    <org_study_id>2905</org_study_id>
    <nct_id>NCT01861847</nct_id>
  </id_info>
  <brief_title>7-Keto DHEA for the Treatment of PTSD</brief_title>
  <official_title>7-Keto DHEA for the Treatment of PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Humanetics Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test the effectiveness of 7-Keto DHEA in reducing
      symptoms of Post-Traumatic Stress Disorder (PTSD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of the study is to investigate the possible effect of 7-Keto
      Dehydroepiandrosterone (7-Keto DHEA) on decreasing Post Traumatic Stress Disorder Symptoms
      (PTSD) in a Veteran population. The study proposes, based on a 2006 report, that the use of
      the drug will show significant reduction in overall PTSD symptoms, a decrease in
      physiological stress response and higher patient-reported quality of life compared to
      placebo. This is a Phase 2, randomized, double-blind, crossover design with a placebo
      control. The sponsor for this study is Humanetics Corporation
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psychological benefits of 7-Keto DHEA (Dehydroepiandrosterone) in Veterans suffering from PTSD participating in the intervention through questionnaires and corresponding measurement of blood work for amounts of DHEA.</measure>
    <time_frame>Four months</time_frame>
    <description>Outcome measures include analysis in symptoms of depression, anxiety, stress, trauma, and improved memory and cognitive functioning after treatment with 7-Keto DHEA. Measures will include psychological questionnaires as follows:
PTSD Checklist (PCL-C) Associated Symptoms of PTSD Scale (ASP) Trauma Symptom Inventory (TSI) Dissociative Experience Scale (DES) Beck Depression Inventory - II (BDI-II) Brief Symptom Inventory (BSI) Quality of Life Inventory (QOLI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiological benefits of 7-Keto DHEA (Dehydroepiandrosterone) in Veterans suffering from PTSD participating in the intervention through questionnaires and corresponding measurement of blood work for amounts of DHEA.</measure>
    <time_frame>Four months</time_frame>
    <description>DHEA (DHEA-S) concentrations (serum, saliva) are often elevated in men and women suffering from PTSD including that related to combat experience. Several studies have shown an association between higher levels of DHEA/DHEA-S and abatement of PTSD symptoms. Outcome measures include analysis of medical assessments via blood work; Complete Blood Count (CBC), Cortisol, and DHEA sulfate level</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>PTSD</condition>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 Keto-DHEA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7-Keto Dehydroepiandrosterone</intervention_name>
    <description>7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.</description>
    <arm_group_label>Drug group</arm_group_label>
    <other_name>7-Keto DHEA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Veteran status and enrolled for care in the Veteran Health Administration

          -  Ages 18-64

          -  Primary diagnosis of PTSD as assess by the clinician administered PTSD scale and
             independent clinical mental health evaluation

        Exclusion Criteria:

          -  psychosis

          -  Dementia

          -  Active alcohol and/or substance abuse or dependence

          -  Active suicidal or homicidal ideation

          -  Medical concerns that would exclude use of 7-Keto DHEA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alina Gonzalez-Mayo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bay Pines VAHCS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bay Pines VA Healthcare System</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2013</study_first_submitted>
  <study_first_submitted_qc>May 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2013</study_first_posted>
  <disposition_first_submitted>September 22, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>October 7, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 29, 2015</disposition_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

